FUTURE ONCOLOGY[ta] - Search Results

Year	Number of Results
2005	95
2006	80
2007	77
2008	82
2009	155
2010	178
2011	131
2012	156
2013	219
2014	294
2015	419
2016	376
2017	357
2018	379
2019	430
2020	405
2021	508
2022	408
2023	284
2024	121

1

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.

Cho BC, Felip E, Hayashi H, Thomas M, Lu S, Besse B, Sun T, Martinez M, Sethi SN, Shreeve SM, Spira AI. Cho BC, et al. Future Oncol. 2022 Feb;18(6):639-647. doi: 10.2217/fon-2021-0923. Epub 2021 Dec 16. Future Oncol. 2022. PMID: 34911336

2

KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.

Rizzo A, Cusmai A, Acquafredda S, Giovannelli F, Rinaldi L, Misino A, Palmiotti G. Rizzo A, et al. Future Oncol. 2022 Jun;18(18):2301-2309. doi: 10.2217/fon-2021-1647. Epub 2022 Apr 5. Future Oncol. 2022. PMID: 35378995 Review.

3

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.

Tsuboi M, Weder W, Escriu C, Blakely C, He J, Dacic S, Yatabe Y, Zeng L, Walding A, Chaft JE. Tsuboi M, et al. Future Oncol. 2021 Nov;17(31):4045-4055. doi: 10.2217/fon-2021-0549. Epub 2021 Jul 19. Future Oncol. 2021. PMID: 34278827 Free PMC article. Clinical Trial.

4

Trastuzumab deruxtecan for HER2+ advanced breast cancer.

Lee J, Park YH. Lee J, et al. Future Oncol. 2022 Jan;18(1):7-19. doi: 10.2217/fon-2021-0550. Epub 2021 Nov 26. Future Oncol. 2022. PMID: 34823373 Review.

5

Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma.

de Castria TB, Khalil DN, Harding JJ, O'Reilly EM, Abou-Alfa GK. de Castria TB, et al. Future Oncol. 2022 Oct;18(33):3769-3782. doi: 10.2217/fon-2022-0652. Epub 2022 Nov 18. Future Oncol. 2022. PMID: 36399155 Review.

6

Surgery for pancreatic cancer: current controversies and challenges.

Karunakaran M, Barreto SG. Karunakaran M, et al. Future Oncol. 2021 Dec;17(36):5135-5162. doi: 10.2217/fon-2021-0533. Epub 2021 Nov 8. Future Oncol. 2021. PMID: 34747183 Review.

7

CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer.

Cetin B, Wabl CA, Gumusay O. Cetin B, et al. Future Oncol. 2022 Mar;18(9):1143-1157. doi: 10.2217/fon-2021-0842. Epub 2022 Feb 9. Future Oncol. 2022. PMID: 35137602 Review.

8

Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.

Furlanetto J, Marmé F, Loibl S. Furlanetto J, et al. Future Oncol. 2022 Sep;18(28):3199-3215. doi: 10.2217/fon-2022-0407. Epub 2022 Sep 7. Future Oncol. 2022. PMID: 36069628 Review.

9

Cancer and COVID-19: analysis of patient outcomes.

Aboueshia M, Hussein MH, Attia AS, Swinford A, Miller P, Omar M, Toraih EA, Saba N, Safah H, Duchesne J, Kandil E. Aboueshia M, et al. Future Oncol. 2021 Sep;17(26):3499-3510. doi: 10.2217/fon-2021-0121. Epub 2021 Jul 15. Future Oncol. 2021. PMID: 34263660 Free PMC article.

10

Oral health-related quality of life in oral cancer patients: systematic review and meta-analysis.

Yuwanati M, Gondivkar S, Sarode SC, Gadbail A, Desai A, Mhaske S, Pathak SK, N Khatib M. Yuwanati M, et al. Future Oncol. 2021 Mar;17(8):979-990. doi: 10.2217/fon-2020-0881. Epub 2021 Feb 5. Future Oncol. 2021. PMID: 33541115

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

4,717 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

4,717 results

Results by year